Anne-SÃ©golÃ¨ne Cottereau

List of Publications by Year
in descending order

47 **papers**	1,516 **citations**	516681 16 **h-index**	330122 37 **g-index**
48 **all docs**	48 **docs citations**	48 **times ranked**	1317 **citing authors**

#	Article	IF	Citations
1	Baseline Metabolic Tumor Volume Predicts Outcome in High–Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. Journal of Clinical Oncology, 2016, 34, 3618-3626.	1.6	231
2	Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Clinical Cancer Research, 2016, 22, 3801-3809.	7.0	151
3	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 2018, 131, 1456-1463.	1.4	130
4	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood, 2020, 135, 1396-1405.	1.4	119
5	^{18}F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome. Journal of Nuclear Medicine, 2020, 61, 40-45.	5.0	109
6	A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies. Journal of Nuclear Medicine, 2022, 63, 172-179.	5.0	96
7	Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT. Annals of Oncology, 2021, 32, 404-411.	1.2	77
8	Deep-Learning ^{18}F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma. Journal of Nuclear Medicine, 2021, 62, 30-36.	5.0	75
9	Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma. Journal of Nuclear Medicine, 2017, 58, 276-281.	5.0	55
10	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. Blood, 2018, 131, 2449-2453.	1.4	49
11	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. Journal of Nuclear Medicine, 2018, 59, 589-595.	5.0	48
12	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Advances, 2021, 5, 539-548.	5.2	38
13	Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. Journal of Clinical Medicine, 2021, 10, 1267.	2.4	27
14	The Role of Interventional Radiology for the Treatment of Hepatic Metastases from Neuroendocrine Tumor: An Updated Review. Journal of Clinical Medicine, 2020, 9, 2302.	2.4	25
15	Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors. Journal of Clinical Medicine, 2019, 8, 1907.	2.4	20
16	Is there an optimal method for measuring baseline metabolic tumor volume in diffuse large B cell lymphoma?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1463-1464.	6.4	19
17	Redifferentiating Effect of Larotrectinib in *NTRK*-Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. Thyroid, 2022, 32, 594-598.	4.5	19
18	Prognostic value of lesion dissemination in doxorubicin, bleomycin, vinblastine, and dacarbazine-treated, interimPET-negative classical Hodgkin Lymphoma patients: A radio-genomic study. Hematological Oncology, 2022, 40, 645-657.	1.7	19

#	Article	IF	Citations
19	Total tumor burden in lymphoma â€" an evolving strong prognostic parameter. British Journal of Radiology, 2021, 94, 20210448.	2.2	18
20	¹⁸F-FDG PET Maximum-Intensity Projections and Artificial Intelligence: A Win-Win Combination to Easily Measure Prognostic Biomarkers in DLBCL Patients. Journal of Nuclear Medicine, 2022, 63, 1925-1932.	5.0	18
21	Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2034-2041.	6.4	15
22	Baseline total metabolic volume (TMTV) to predict the outcome of patients with advanced Hodgkin lymphoma (HL) enrolled in the AHL2011 LYSA trial.. Journal of Clinical Oncology, 2016, 34, 7509-7509.	1.6	15
23	Adrenal Mass Characterization in the Era of Quantitative Imaging: State of the Art. Cancers, 2022, 14, 569.	3.7	15
24	Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCLâ€"Response. Clinical Cancer Research, 2016, 22, 3414-3415.	7.0	14
25	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers, 2021, 13, 2448.	3.7	13
26	New Approaches in Characterization of Lesions Dissemination in DLBCL Patients on Baseline PET/CT. Cancers, 2021, 13, 3998.	3.7	12
27	Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica, 2022, 107, 1681-1686.	3.5	12
28	Surgical management of insulinoma over three decades. Hpb, 2021, 23, 1799-1806.	0.3	11
29	Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2020, 9, 1860.	2.4	10
30	Neuroendocrine Carcinomas of the Digestive Tract: What Is New?. Cancers, 2021, 13, 3766.	3.7	10
31	Focal splenic lesions: Imaging spectrum of diseases on CT, MRI and PET/CT. Diagnostic and Interventional Imaging, 2021, 102, 501-513.	3.2	9
32	Deep Learning Approach to Automatize TMTV Calculations Regardless of Segmentation Methodology for Major FDG-Avid Lymphomas. Diagnostics, 2022, 12, 417.	2.6	9
33	FDG-PET in PMBCL: which heterogeneity?. Blood, 2018, 132, 117-118.	1.4	4
34	Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma. Radiology, 2018, 286, 560-567.	7.3	3
35	Visualization of Macroprolactinoma by 18F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1. Journal of the Endocrine Society, 2018, 2, 1170-1172.	0.2	3
36	Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma. Blood, 2021, 138, 880-880.	1.4	3

#	Article	IF	Citations
37	Amahrelis : Adcetris Maintenance after Autologous Stem Cell Transplantation in Hodgkin Lymphoma : A Real Life Study from Sfgmtc and Lysa Groups. Blood, 2020, 136, 20-21.	1.4	3
38	18F-fluorocholine PET/CT and conventional imaging in primary hyperparathyroidism. Diagnostic and Interventional Imaging, 2022, 103, 258-265.	3.2	3
39	Brain 18F-FDG, 18F-Florbetaben PET/CT, 123I-FP-CIT SPECT and Cardiac 123I-MIBG Imaging for Diagnosis of a "Cerebral Type" of Lewy Body Disease. Nuclear Medicine and Molecular Imaging, 2016, 50, 258-260.	1.0	2
40	Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement. Anti-Cancer Drugs, 2021, 32, 1118-1122.	1.4	2
41	Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy. Cancers, 2021, 13, 4323.	3.7	2
42	The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World. Blood, 2020, 136, 30-31.	1.4	2
43	PET imaging: back in the game for gastric EMZL?. Blood, 2022, 139, 154-155.	1.4	1
44	Prolonged response to 177Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor. Investigational New Drugs, 2020, 38, 1196-1199.	2.6	0
45	A pheochromocytoma wrapped in an IgG4-related disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 929-930.	6.4	0
46	Recurrence of a Pheochromocytoma With TNEM127 Mutation Negative on 18F-FDOPA and 18F-FDG but Positive on 123I-MIBG and 68Ga-DOTATOC Imaging. Clinical Nuclear Medicine, 2022, 47, 251-252.	1.3	0
47	Malignant histiocytosis with a Langerhans cell subtype: A report on the diagnostic and therapeutic challenge. Blood Cells, Molecules, and Diseases, 2021, 92, 102623.	1.4	0